ストックスクリーナーアプリを入手
2.60
4.42%
0.11
プレマーケット:
2.60
前日終値:
$2.49
開ける：
$2.45
24時間の取引高:
546.82K
Relative Volume:
0.42
時価総額：
$24.15M
収益：
-
当期純損益:
$-45.57M
株価収益率:
-0.4127
EPS:
-6.3
ネットキャッシュフロー:
$-38.56M
1週間 パフォーマンス:
-8.45%
1か月 パフォーマンス:
+44.44%
6か月 パフォーマンス:
-36.59%
1年 パフォーマンス:
-10.65%
1日の値動き範囲:
$2.43
$2.85
1週間の範囲:
$2.245
$6.60
52週間の値動き範囲:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
SABS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.60 | 23.13M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc (SABS) 最新ニュース
Is SAB Biotherapeutics Inc. a good long term investmentUnmatched profit growth - PrintWeekIndia
How SAB Biotherapeutics Inc. stock reacts to Fed policy changesExceptional market positioning - jammulinksnews.com
What analysts say about SAB Biotherapeutics Inc. stockFree Investment Portfolio Suggestions - Autocar Professional
How SAB Biotherapeutics Inc. Equity Warrant stock reacts to Fed policy changesMarket-beating performance - jammulinksnews.com
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement - MSN
Is SAB Biotherapeutics Inc. Equity Warrant a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
SAB Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - Autocar Professional
SAB Biotherapeutics Plunges 10.34% on Private Placement Concerns - AInvest
What drives SAB Biotherapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com
What drives SAB Biotherapeutics Inc. Equity Warrant stock priceBreakthrough profit margins - jammulinksnews.com
What analysts say about SAB Biotherapeutics Inc. Equity Warrant stockExceptional financial outcomes - jammulinksnews.com
SAB Biotherapeutics Inc. Equity Warrant Stock Analysis and ForecastExplosive trading growth - jammulinksnews.com
SAB Biotherapeutics stock price target lowered to $9 by H.C. Wainwright - Investing.com Canada
SAB Biotherapeutics Stock Surges 5.06% to Rank 277th in Trading Volume - AInvest
SAB Biotherapeutics stock price target raised to $14 from $12 at Oppenheimer - Investing.com Canada
SAB Biotherapeutics Inc (SABS) Stock: A Year of Market Movement, Down and Up - investchronicle.com
SABS Soars 24.5% on Volatile Intraday Surge—What’s Fueling the Biotech Rally? - AInvest
SAB Biotherapeutics (SABS) up more than 100% since Jun 30 - AInvest
SABS Surges 42%—Volatile Rally Reaches 52-Week High Amid Market Turbulence - AInvest
Sab Biotherapeutics shares rise 144.48% intraday after raising $175 million in private placement. - AInvest
SAB Biotherapeutics Stock Surge: Should You Buy? - StocksToTrade
SAB Biotherapeutics stock soars after securing $175 million private placement By Investing.com - Investing.com Nigeria
SAB Biotherapeutics stock soars after securing $175 million private placement - Investing.com India
SAB BIO Stock Explodes 54% on Game-Changing $175 Million Private Placement Deal - RagingBull
SAB Biotherapeutics Secures $175M in Private Placement - TipRanks
SAB Biotherapeutics announces oversubscribed $175M private placement - TipRanks
SAB BIO Announces Oversubscribed $175 Million Private Placement - GlobeNewswire
SAB BIO Secures $175M Funding Led by Sanofi to Advance Revolutionary Type 1 Diabetes Treatment Through 2028 - Stock Titan
SABS Stock on the Rise: What’s Next? - timothysykes.com
Published on: 2025-07-20 20:52:24 - jammulinksnews.com
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):